The downregulation of TLRs and CCR5 observed upon AXL inhibition suggests a potential mechanism by which AXL antagonism may attenuate the inflammatory response in MASLD/MASH. This evidence concerns the gene AXL and metabolic dysfunction-associated steatotic liver disease.